Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice
Journal of Clinical Investigation · 03.11.2025 · 135 (21)
DOI: 10.1172/jci194080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 23.09.2025. Verfasst von Yrina Rochman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Nanoparticles, Asthma, RNA, Messenger, Allergens. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Food Allergy Fund.
Abstract (Originalsprache)
Allergic diseases have reached epidemic proportions globally, calling attention to the need for better treatment and preventive approaches. Herein, we developed allergen-encoding messenger RNA (mRNA)–lipid nanoparticle (LNP) strategies for both therapy and prevention of allergic responses. Immunization with allergen-encoded mRNA-LNPs modulated T cell differentiation, inhibiting the generation of T helper type 2 and type 17 cells upon allergen exposure in experimental asthma models induced by ovalbumin, and naturally occurring house dust mite (HDM) and the major HDM allergen Der p1. Allergen-specific mRNA-LNP treatment attenuated clinicopathology in both preventive and established allergy models, including reduction in eosinophilia, mucus production, and airway hypersensitivity, while enhancing production of allergen-specific IgG antibodies and maintaining low IgE levels. Additionally, allergen-specific mRNA-LNP vaccines in mice elicited a CD8 + CD38 + KLRG – T cell response as seen following SARS-CoV-2 mRNA vaccination in humans, underscoring a conserved immune mechanism across species, regardless of the mRNA-encoded protein. Notably, mRNA-LNP vaccination in combination with an mTOR inhibitor reduced the CD8 + T cell response without affecting the vaccine-induced anti-allergic effect in the preventive model of asthma. This technology renders allergen-specific mRNA-LNP therapy a promising approach for prevention and treatment of allergic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Pennsylvania, USA.
- Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
- Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Food Allergy Fund
Zitieren
APA
Rochman, Y., Kotliar, M., Klingler, A. M., Rochman, M., Alameh, M. G., Melamed, J. R., Osswald, G. A., Caldwell, J. M., Felton, J. M., Mack, L. E., Hargis, J., Lewkowich, I. P., Barski, A., Weissman, D., & Rothenberg, M. E. (2025). Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice. Journal of Clinical Investigation, 135(21). https://doi.org/10.1172/jci194080
Vancouver
Rochman Y, Kotliar M, Klingler AM, Rochman M, Alameh MG, Melamed JR, et al. Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice. Journal of Clinical Investigation. 2025;135(21). doi:10.1172/jci194080
BibTeX
@article{Rochman2025,
author = {Rochman, Yrina and Kotliar, Michael and Klingler, Andrea M and Rochman, Mark and Alameh, Mohamad-Gabriel and Melamed, Jilian R and Osswald, Garrett A and Caldwell, Julie M and Felton, Jennifer M and Mack, Lydia E and Hargis, Julie and Lewkowich, Ian P and Barski, Artem and Weissman, Drew and Rothenberg, Marc E},
title = {Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {21},
doi = {10.1172/jci194080}
}
EUVIMED